Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (08HH.SG)
| Previous Close | 1.5510 |
| Open | 1.5280 |
| Bid | 1.5370 x 700000 |
| Ask | 1.6030 x 1100000 |
| Day's Range | 1.5280 - 1.5280 |
| 52 Week Range | 1.3390 - 2.4020 |
| Volume | |
| Avg. Volume | 98 |
| Market Cap | 6.752B |
| Beta (5Y Monthly) | 0.62 |
| PE Ratio (TTM) | 15.28 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 0.04 (2.28%) |
| Ex-Dividend Date | Jul 26, 2024 |
| 1y Target Est | N/A |
- Investing.com
Cevira Phase III trial for non-surgical HSIL treatment meets primary endpoint
Photocure ASA (OSE: PHO) and its partner Asieris Pharmaceuticals (SSE (LON:SSE): 688176) announced on Wednesday that their multinational Phase III clinical trial for Cevira (APL-1702) has successfully met its primary endpoint. Cevira, a photodynamic drug-device combination product, is in development for the non-surgical treatment of high-grade squamous intraepithelial lesions (HSIL).
- Reuters
India's Gland Pharma posts 41% jump in quarterly revenue on Cenexi acquisition
Indian generic injectables maker Gland Pharma Ltd reported a 41% jump in first-quarter revenue on Monday, aided by its acquisition of French pharmaceutical group Cenexi. The Hyderabad-based company, which draws the bulk of its revenue from the United States, Europe, Canada, Australia and New Zealand, said revenue jumped to 12.09 billion Indian rupees ($146.13 million) from 8.57 billion rupees. The company said 37% of the total revenue came from its acquisition of Cenexi in January.
